https://peptidecost.com/a-manu....script-technique-of-
© The Author(s) 2020. Posted by Oxford University Press on behalf of the European community of Cardiology.Apixaban is well examined in adults; paediatric data tend to be extremely restricted. We explain 3 children (age 2-6 years, fat 13-17 kg) with congenital cardiovascular disease who developed intracardiac thrombosis, plus in who typical treatments had unsuccessful (in 1) or were considered not practical (in 2). All had been addressed with apixaban 2.5 mg orally twice day-to-day with
Like
Comment
Share
